Studies

Current Development Plan

Target

Relapsing myeloma

Trial Number

2016-001564-11

Trial Description

VIRel: Viral immunotherapy in relapsed/refractory multiple myeloma - a phase I study to assess the safety and tolerability of REOLYSIN® (pelareorep) in combination with lenalidomide or pomalidomide.

Enrollment Status

Ongoing

Locations

St James' Hospital, Leeds UK
The Christie Hospital, Manchester UK

About

Relapsed multiple myeloma, also known as recurrent myeloma, is when the cancer returns after treatment or a period of remission. Due to multiple myeloma not having a cure, it’s likely that at some point patients will relapse.

View Clinical Trial

Target

Pancreatic Cancer

Trial Number

NCT02620423

Trial Description

Intravenous administration of REOLYSIN® in combination with pembrolizumab (KEYTRUDA®) and chemotherapy in patients with advanced or metastatic pancreatic adenocarcinoma.

Enrollment Status

Complete

Locations

San Antonio, TX

About

Pancreatic cancer arises when cells in the pancreas, a glandular organ behind the stomach, begin to multiply out of control and form a mass.

View Clinical Trial

Target

Breast Cancer

Trial Number

NCT01656538

Trial Description

Intravenous administration of REOLYSIN in combination with paclitaxel for patients with advanced or metastatic breast cancer.

Enrollment Status

Complete

Locations

British Columbia, Canada
Ontario, Canada
Saskatchewan, Canada

About

Breast cancer is cancer that develops from breast tissue.

View Clinical Trial

Target

Pancreatic Cancer

Trial Number

NCT01280058

Trial Description

Intravenous administration of REOLYSIN in combination with paclitaxel and carboplatin for patients with metastatic pancreatic cancer.

Enrollment Status

Complete

Locations

The Ohio State University Comprehensive Cancer Center, Columbus, OH
Georgetown University, Washington, DC
Oklahoma Cancer Center, Oklahoma City, OK
Emory University Winship Cancer Institute, Atlanta, GA
Montefiore Medical Center, Bronx, NY

About

Pancreatic cancer arises when cells in the pancreas, a glandular organ behind the stomach, begin to multiply out of control and form a mass.

View Clinical Trial

Target

Pancreatic Cancer

Trial Number

NCT00998322

Trial Description

Intravenous administration of REOLYSIN in combination with gemcitabine (Gemzar®) for patients with advanced or metastatic pancreatic cancer.

Enrollment Status

Complete

Locations

New York, NY
San Antonio, TX

About

Pancreatic cancer arises when cells in the pancreas, a glandular organ behind the stomach, begin to multiply out of control and form a mass.

View Clinical Trial

Legacy Studies

Trial Description

Intravenous administration of REOLYSIN in combination with dexamethasone and carfilzomib for patients with relapsed or refractory myeloma.

Enrollment Status

Complete

About

Multiple myeloma, also known as plasma cell myeloma, is a cancer of plasma cells, a type of white blood cell normally responsible for producing antibodies.

Trial Description

Intravenous administration of REOLYSIN in combination with FOLFIRI and bevacizumab (Avastin®) in folfiri-naïve patients with mutant metastatic colorectal cancer.

Enrollment Status

Complete

About

Colorectal cancer (CRC), also known as bowel cancer and colon cancer, is the development of cancer from the colon or rectum (parts of the large intestine).